LCG
SGMO

Lisanti Capital Growth’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Lisanti Capital Growth’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-80,300
Closed -$1.26M – 100
2015
Q1 		$1.26M Buy
+80,300
New +$1.24M 0.72% 74
2014
Q3 		– Sell
-35,730
Closed -$546K – 106
2014
Q2 		$546K Buy
+35,730
New +$514K 0.24% 94

Other funds holding SGMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Lisanti Capital Growth's SGMO Position: Q2 2015 in Review

Lisanti Capital Growth sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2015, closing a stake of 80,300 shares — an estimated $1.26M sold.

Lisanti Capital Growth first reported a position in SGMO in Q2 2014 and held it in 2 quarters. The position peaked at $1.26M in Q1 2015. 156 funds tracked by Wall St. Rank hold SGMO as of Q2 2015.

  • Lisanti Capital Growth reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2015 after selling out during the quarter.
  • Lisanti Capital Growth sold 80,300 SANGAMO THERAPEUTICS INC shares in Q2 2015, an estimated $1.26M.
  • Lisanti Capital Growth first reported a position in SANGAMO THERAPEUTICS INC in Q2 2014 and held it in 2 quarters.
  • Lisanti Capital Growth's SANGAMO THERAPEUTICS INC position peaked at $1.26M in Q1 2015.
  • 156 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2015.

Based on Lisanti Capital Growth's 13F filing for Q2 2015, filed 24 Jul 2015.